产品名称 | NebuSelect™ Recombinant Mouse PCSK9, His-tag |
---|---|
目录号 | NBL-242212 |
别名 | PCSK9; PC9; PCSK9; FH3; HCHOLA3; LDLCQ1; NARC-1 |
外观 | see COA |
分子量 | Gln35-Gln694 |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | Q80W65 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-242212-100ug | 100ug | Inquire | Inquire | |
NBL-242212-1mg | 1mg | Inquire | Inquire | |
NBL-242212-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Mouse PCSK9, His-tag
Catalog#:
NBL-242212
Description:
NebuSelect™ Recombinant Mouse PCSK9, His-tag(Cat#NBL-242212) is expressed in HEK293 with His tag at the C-Terminus.It contains Gln35-Gln694.
Species:
Mouse
Expression System:
HEK293
Molecular Weight:
Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-68 kDa (pro-form) and 15kDa (mature form) based on Bis-Tris PAGE result.
Target Name:
PCSK9; PC9; PCSK9; FH3; HCHOLA3; LDLCQ1; NARC-1
Target Information:
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
Amino Acid Sequence:
Gln35-Gln694
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.